New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Impaired Activity of Blood Coagulant Factor XIII in Patients with Necrotizing Enterocolitis
Impaired Activity of Blood Coagulant Factor XIII in Patients with Necrotizing Enterocolitis SCIENTIFIC REPORTS Tao, G., Liu, B., Zhang, R., Liu, G., Abdullah, F., Harris, M. C., Brandt, M. L., Ehrenkranz, R. A., Bowers, C., Martin, C. R., Moss, R. L., Sylvester, K. G. 2015; 5Abstract
Necrotizing enterocolitis (NEC) is the most common gastrointestinal (GI) medical/surgical emergency of the newborn and a leading cause of preterm neonate morbidity and mortality. NEC is a challenge to diagnose since it often shares similar clinical features with neonatal sepsis. In the present study, plasma protein profiling was compared among NEC, sepsis and control cohorts using gel electrophoresis, immunoblot and mass spectrometry. We observed significant impairment in the formation of fibrinogen-? dimers (FGG-dimer) in the plasma of newborns with NEC that could efficiently differentiate NEC and sepsis with a high level of sensitivity and specificity. Interestingly, the impaired FGG-dimer formation could be restored in NEC plasma by the addition of exogenous active factor XIII (FXIII). Enzymatic activity of FXIII was determined to be significantly lower in NEC subject plasma for crosslinking FGG when compared to sepsis. These findings demonstrate a potential novel biomarker and related biologic mechanism for diagnosing NEC, as well as suggest a possible therapeutic strategy.
View details for DOI 10.1038/srep13119
View details for Web of Science ID 000359525400001